Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Rating) by 11.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 98,200 shares of the biotechnology company’s stock after buying an additional 9,900 shares during the quarter. New York State Common Retirement Fund owned approximately 0.11% of Sarepta Therapeutics worth $8,843,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Janus Henderson Group PLC raised its position in Sarepta Therapeutics by 7.3% in the third quarter. Janus Henderson Group PLC now owns 7,398,598 shares of the biotechnology company’s stock valued at $684,205,000 after purchasing an additional 503,833 shares during the period. Point72 Asset Management L.P. increased its position in Sarepta Therapeutics by 341.0% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,846,000 shares of the biotechnology company’s stock worth $170,718,000 after purchasing an additional 1,427,400 shares during the last quarter. Casdin Capital LLC increased its holdings in shares of Sarepta Therapeutics by 24.3% during the 3rd quarter. Casdin Capital LLC now owns 1,100,000 shares of the biotechnology company’s stock valued at $101,728,000 after acquiring an additional 215,000 shares during the last quarter. Bellevue Group AG acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter valued at about $52,637,000. Finally, Camber Capital Management LP acquired a new stake in Sarepta Therapeutics in the 3rd quarter valued at approximately $46,240,000. Institutional investors own 75.64% of the company’s stock.

Several equities analysts have issued reports on SRPT shares. StockNews.com initiated coverage on Sarepta Therapeutics in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Needham & Company LLC reissued a “buy” rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, January 11th. Barclays cut their price target on Sarepta Therapeutics from $125.00 to $104.00 in a report on Wednesday, March 2nd. Morgan Stanley dropped their target price on Sarepta Therapeutics from $80.00 to $77.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 12th. Finally, Royal Bank of Canada boosted their price target on Sarepta Therapeutics from $145.00 to $150.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 2nd. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Buy” and an average price target of $115.42.

NASDAQ SRPT opened at $76.40 on Friday. The company has a 50-day simple moving average of $80.01 and a two-hundred day simple moving average of $81.11. The company has a quick ratio of 5.34, a current ratio of 5.75 and a debt-to-equity ratio of 1.18. Sarepta Therapeutics, Inc. has a 12-month low of $61.31 and a 12-month high of $101.24. The firm has a market cap of $6.66 billion, a price-to-earnings ratio of -14.86 and a beta of 1.30.

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) last announced its earnings results on Tuesday, March 1st. The biotechnology company reported ($1.42) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.51) by $0.09. Sarepta Therapeutics had a negative net margin of 59.67% and a negative return on equity of 69.28%. The business had revenue of $201.50 million during the quarter, compared to the consensus estimate of $198.48 million. During the same quarter last year, the firm earned ($2.40) earnings per share. The business’s revenue for the quarter was up 38.9% on a year-over-year basis. Equities analysts expect that Sarepta Therapeutics, Inc. will post -5.15 earnings per share for the current fiscal year.

Sarepta Therapeutics Profile (Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

See Also

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.